Apellis Pharmaceuticals, Inc. has achieved a significant milestone with the approval of Empaveli (pegcetacoplan) by the US Food and Drug Administration (FDA) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 and above, aimed at reducing proteinuria. These rare kidney diseases, affecting around 5,000 individuals in the United States, have long lacked effective treatment options.
The approval of Empaveli marks a pivotal moment in the management of these severe conditions, potentially saving patients from progressing to kidney failure, which often necessitates lifelong dialysis or kidney transplant. Led by Dr. Carla Nester, the phase 3 VALIANT study demonstrated Empaveli’s remarkable efficacy, showcasing a 68% reduction in proteinuria, kidney function stabilization, and significant clearance of C3 deposits compared to placebo. This breakthrough therapy has the potential to transform the lives of patients with C3G and primary IC-MPGN by targeting the underlying disease mechanisms effectively.
Read more from pharmabiz.com